This module describes the datasets that are available for the analyses of molecular response to Immune Checkpoint Inhibitor Inhibitors (ICI). 

These datasets consist of genomics data with annotated clinical data associated with immuno-oncology clinical trials, obtained from the following sources:

- Auslander et al., Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma, [Nature Medicine](https://www.nature.com/articles/s41591-018-0157-9) (2018)
- Gide et al., Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy, [Cancer Cell](https://www.sciencedirect.com/science/article/abs/pii/S1535610819300376) (2019)
- Hugo et al., Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma, [Cell](https://www.sciencedirect.com/science/article/pii/S009286741630215X) (2016)
-  IMvigor210 Study Group, Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial, [The Lancet](https://www.sciencedirect.com/science/article/pii/S0140673616324552?via%3Dihub) (2017)
- Prins et al., Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma, [Nature Medicine](https://www.nature.com/articles/s41591-018-0337-7) (2019)
- Riaz et al., Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab, [Cell](https://www.sciencedirect.com/science/article/pii/S0092867417311224) (2017)
- Van Allen et al., Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, [Science](https://science.sciencemag.org/content/350/6257/207.long) (2015)








